Cardiol Therapeutics announced that the United States Patent and Trademark Office granted a patent allowance for its ‘Cannabidiol Compositions for Use in Treating Heart Conditions’ application on November 13, 2025. The allowance covers the company’s oral CardiolRx and the subcutaneous formulation CRD‑38, extending protection through October 2040 and providing a nearly 15‑year exclusivity window that aligns with the expected launch of its Phase III MAVERIC trial and the first‑in‑human studies of CRD‑38.
The patent’s breadth—encompassing heart failure, myocarditis, pericarditis, atherosclerosis and inflammatory cardiomyopathies—creates a robust intellectual‑property moat. By securing rights to both a small‑molecule anti‑inflammatory agent and a novel subcutaneous delivery platform, Cardiol positions itself to capture a sizable share of the growing heart‑failure and pericarditis markets while shielding its investment in clinical development from generic or biosimilar competition.
On the same day, Cardiol reported its third‑quarter 2025 earnings. The company posted an earnings per share of –$0.09, matching consensus estimates of –$0.09. The flat EPS result reflects disciplined cost management amid modest revenue growth, as the company continues to invest heavily in its Phase III MAVERIC trial and the preclinical development of CRD‑38. Management noted that the company’s operating expenses remained in line with prior periods, and that the company’s cash runway extends into the third quarter of 2027 following an $11.4 million financing round in October.
CEO David Elsley emphasized that the patent milestone “extends our IP protection to the world’s largest pharmaceutical market” and that it “fortifies the company’s market position and IP portfolio, providing broad protection across diverse heart diseases.” Chief Medical Officer Andrew Hamer added that the timing of the allowance “comes at an opportune moment, adding protection in new areas of heart disease identified for potential research expansion based on ARCHER findings.”
Cardiol’s pipeline remains on track: the Phase III MAVERIC trial for recurrent pericarditis is accelerating enrollment, and the company plans to present Phase II ARCHER trial results on November 29, 2025. The patent allowance, coupled with the company’s ongoing clinical progress and recent financing, strengthens Cardiol’s long‑term commercialization strategy and positions it to capitalize on the high‑cost, high‑need heart‑failure market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.